This article has Open Peer Review reports available.
Gastric malignant schwannoma presenting with upper gastrointestinal bleeding: a case report
© Takemura et al; licensee BioMed Central Ltd. 2012
Received: 1 August 2011
Accepted: 25 January 2012
Published: 25 January 2012
We report a case of gastric malignant schwannoma presenting with gastrointestinal bleeding.
A 70-year-old Japanese man presented with gastrointestinal bleeding to our hospital. Gastrointestinal endoscopy revealed a protruding lesion in the gastric body. Hematoxylin and eosin staining of biopsy specimens from this lesion revealed sheets of spindle cells. Immunohistochemistry revealed that these cells were positive for S-100 protein and negative for c-Kit and smooth muscle actin. Because mitosis was diffusely visible, this tumor was diagnosed as a gastric malignant schwannoma. Distal gastrectomy with lymph node dissection was performed and the patient's postoperative course was uneventful. However, five months after the surgery, he died from multiple liver metastases.
Cases of gastric malignant schwannoma have rarely been reported. The efficacy of surgical resection and postoperative prognosis continues to remain unclear and should be investigated further.
Schwannomas are neurogenic tumors that originate from different organs as well as other areas throughout the body. Gastric schwannomas are rare; however, if they do occur in the gastrointestinal tract, the most common site is the stomach. Gastric schwannomas represent 0.2% of all gastric neoplasms . Gastrointestinal endoscopy, such as endosonography, is the principal diagnostic tool for gastric schwannoma . However, differentiating a schwannoma from other gastric submucosal tumors is often difficult. The definitive diagnosis of gastric schwannoma is established by pathological and immunohistochemical examination of resected surgical specimens .
Schwannomas are generally benign. Complete surgical removal is sufficient treatment for a benign gastric schwannoma because of excellent postoperative prognosis. Gastric malignant schwannomas are extremely rare and only a few cases have been reported [4, 5]. We present the case of a 70-year-old man who presented with gastrointestinal bleeding because of gastric malignant schwannoma.
Schwannomas, also known as neurinomas and neurilemomas, are rare stromal tumors of spindle cells of the gastrointestinal tract that arise from the schwann cells of the gastrointestinal neural plexus. The stomach is the most common gastrointestinal site of schwannomas, which constitute 0.2% of gastric neoplasms [1, 3]. Gastric schwannomas frequently occur in individuals 30 to 50 years old and are usually solitary lesions arising from the lesser curvature of the stomach [1, 3, 6].
Spindle cell tumors of the gastrointestinal tract are slow growing and covered with normal mucosa; they principally involve the submucosa and muscularis propria. The majority of spindle cell tumors of the gastrointestinal tract are believed to originate from the smooth muscle tissue. However, immunohistochemical staining has enabled differentiation of various spindle cell tumors . Schwannomas can be distinguished from other spindle cell tumors of the stomach by S-100 protein staining. Tumor cells that are positive for S-100 protein and negative for smooth muscle actin, c-Kit and CD34 support the diagnosis of a schwannoma [7, 8].
Preoperative differential diagnosis of gastric submucosal tumors is generally difficult. Computed tomography and gastrointestinal endoscopy are of limited use when attempting a definitive diagnosis of a gastric submucosal tumor . Hoda et al. reported that endoscopic ultrasound (EUS)-guided sampling of gastrointestinal submucosal lesions is helpful . They concluded that the diagnostic yield of EUS-fine needle aspiration (FNA) was 83.9% and that FNA can be used to establish a definite or probable diagnosis in the majority of patients with spindle cell tumors of the gastrointestinal tract. 18F-fluorodeoxyglucose positron emission tomography (FDG-PET) is a non-invasive diagnostic technique that enables quantification of tumor activity on the basis of altered tissue glucose metabolism. Recently, FDG-PET has been accepted as a powerful diagnostic tool for evaluating various tumors, even spindle cell tumors within the gastrointestinal tract [10–12]. Benz et al. demonstrated that FDG-PET can reliably discriminate malignant peripheral nerve sheath tumors from benign ones . However, reports on the utility of FDG-PET for diagnosing gastric schwannomas are rare. Komatsu et al. reported a case of gastric schwannoma reflected by increased FDG uptake . However, they showed that gastric schwannomas cannot be differentiated from gastrointestinal stromal tumors by FDG accumulation and that FDG-PET was not helpful for evaluating whether the tumors are benign or malignant. Therefore, further studies are required to clarify the utility of FDG-PET in the diagnosis of gastric schwannoma.
Bruneton et al. reviewed 112 cases of gastric schwannoma and found that the majority of the cases (63%) reported gastrointestinal bleeding as the first symptom and 42% presented with abdominal pain . Gastrointestinal bleeding may be present in a case with deep ulceration due to gastric activity or ischemic changes in the covering mucosa and/or a schwannoma. The remaining patients had non-specific abdominal discomfort. In our patient who had gastrointestinal bleeding, the covering mucosa was found to be ulcerated during gastrointestinal endoscopy.
Gastric malignant schwannomas can be distinguished from benign schwannomas on the basis of histological examination of the resected specimens, not by clinical symptoms or imaging studies. The treatment strategy for gastric schwannoma is, therefore, the same regardless of whether the tumor is malignant or benign. Surgical resection is the only possible treatment for gastric schwannoma [1, 14]. The postoperative prognosis for solitary benign schwannoma is excellent. Recurrent disease is generally associated with an incomplete surgical margin. Additionally, recent advances in molecular or target therapy have an important role for the treatment of gastrointestinal mesenchimal tumors. However, the usefulness of molecular therapy for gastric schwannoma is not clearly established because only a few cases with gastric schwannoma have been reported. On the other hand, Xabier et al. reported that there is a high expression rate of platelet-derived growth factor receptor (PDGFR) and c-kit in vestibular schwannoma . They concluded that direct inhibition of these molecules by Gleevec® (imatinib mesylate)may have relevant therapeutic applications for this kind of tumor. From these results, molecular therapy for gastric schwannoma may become an additional treatment modality and deserves further examination.
Gastric malignant schwannomas are extremely rare, and only a few cases have been reported. Given the paucity of the currently available published literature, the efficacy of surgical resection and postoperative prognosis for such cases warrants further study.
Written informed consent was obtained from the patient for publication of this case report and any accompanying images. A copy of the written consent is available for review by the Editor-in-Chief of this journal.
- Melvin WS, Wilkinson MG: Gastric schwannoma. Clinical and pathologic considerations. Am Surg. 1993, 59: 293-296.PubMedGoogle Scholar
- Hoda KM, Rodriguez SA, Faigel DO: EUS-guided sampling of suspected GI stromal tumors. Gastrointest Endosc. 2009, 69: 1218-1223. 10.1016/j.gie.2008.09.045.View ArticlePubMedGoogle Scholar
- Daimaru Y, Kido H, Hashimoto H, Enjoji M: Benign schwannoma of the gastrointestinal tract: a clinicopathologic and immunohistochemical study. Hum Pathol. 1988, 19: 257-264. 10.1016/S0046-8177(88)80518-5.View ArticlePubMedGoogle Scholar
- Loffeld RJ, Balk TG, Oomen JL, van der Putten AB: Upper gastrointestinal bleeding due to a malignant Schwannoma of the stomach. Eur J Gastroenterol Hepatol. 1998, 10: 159-162. 10.1097/00042737-199802000-00012.View ArticlePubMedGoogle Scholar
- Bees NR, Ng CS, Dicks-Mireaux C, Kiely EM: Gastric malignant schwannoma in a child. Br J Radiol. 1997, 70: 952-955.View ArticlePubMedGoogle Scholar
- Sarlomo-Rikala M, Miettinen M: Gastric schwannoma--a clinicopathological analysis of six cases. Histopathology. 1995, 27: 355-360. 10.1111/j.1365-2559.1995.tb01526.x.View ArticlePubMedGoogle Scholar
- Miettinen M, Sarlomo-Rikala M, Lasota J: Gastrointestinal stromal tumors. Ann Chir Gynaecol. 1998, 87: 278-281.PubMedGoogle Scholar
- Miettinen M, Lasota J: Gastrointestinal stromal tumors--definition, clinical, histological, immunohistochemical, and molecular genetic features and differential diagnosis. Virchows Arch. 2001, 438: 1-12. 10.1007/s004280000338.View ArticlePubMedGoogle Scholar
- Vinhais SN, Cabrera RA, Nobre-Leitão C, Cunha TM: Schwannoma of the esophagus: computed tomography and endosonographic findings of a special type of schwannoma. Acta Radiol. 2004, 45: 718-720. 10.1080/02841850410008243.View ArticlePubMedGoogle Scholar
- Benz MR, Czernin J, Dry SM, Tap WD, Allen-Auerbach MS, Elashoff D, Phelps ME, Weber WA, Eilber FC: Quantitative F18-fluorodeoxyglucose positron emission tomography accurately characterizes peripheral nerve sheath tumors as malignant or benign. Cancer. 2010, 116: 451-458. 10.1002/cncr.24755.View ArticlePubMedPubMed CentralGoogle Scholar
- Otomi Y, Otsuka H, Morita N, Terazawa K, Furutani K, Harada M, Nishitani H: Relationship between FDG uptake and the pathological risk category in gastrointestinal stromal tumors. J Med Invest. 2010, 57: 270-274. 10.2152/jmi.57.270.View ArticlePubMedGoogle Scholar
- Komatsu D, Koide N, Hiraga R, Furuya N, Akamatsu T, Uehara T, Miyagawa S: Gastric schwannoma exhibiting increased fluorodeoxyglucose uptake. Gastric Cancer. 2009, 12: 225-228. 10.1007/s10120-009-0526-7.View ArticlePubMedGoogle Scholar
- Bruneton JN, Drouillard J, Roux P, Ettore F, Lecomte P: Neurogenic tumors of the stomach. Report of 18 cases and review of the literature. Rofo. 1983, 139: 192-198. 10.1055/s-2008-1055869.View ArticlePubMedGoogle Scholar
- Prévot S, Bienvenu L, Vaillant JC, de Saint-Maur PP: Benign schwannoma of the digestive tract: a clinicopathologic and immunohistochemical study of five cases, including a case of esophageal tumor. Am J Surg Pathol. 1999, 23: 431-436. 10.1097/00000478-199904000-00007.View ArticlePubMedGoogle Scholar
- Altuna X, Lopez JP, Yu MA, Arandazi MJ, Harris JP, Wang-Rodriguez J, An Y, Dobrow R, Doherty JK, Ongkeko WM: Potential role of Imatinib Mesylate (Gleevec°, STI-571) in the treatment of vestibular schwannoma. Otol Neurotol. 2011, 32 (1): 163-170. 10.1097/MAO.0b013e3182009665.View ArticlePubMedGoogle Scholar
This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.